The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | Ibrutinib induces hypertension and cardiac arrhythmia by targeting CaV1.2 calcium channels
In this video, Juejin Wang, MD, PhD, Nanjing Medical University, Nanjing, China, presents preliminary data into the investigation of the underlying mechanisms which may cause hypertension and cardiac arrhythmia in many patients with chronic lymphocytic leukemia (CLL) who are treated with ibrutinib. Through isolating arteries of animal models, Dr Wang and his team found upregulation of the CaV1.2 calcium channel, which may therefore be a target for controlling hypertension in ibrutinib-treated patients in the future. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
